EUVIMEDEUVIMED entdecken
VergleichsstudieRandomisierte kontrollierte StudieOpen Access

Comparative efficacy and safety of olezarsen versus volanesorsen for familial chylomicronemia syndrome: a matching-adjusted indirect comparison

Handrean Soran, Asia Sikora Kessler iD, Montserrat Vera-Llonch iD, Veronica J Alexander iD, Paul Serafini iD, Divya Pushkarna iD, Elisabete Rodrigues, Erik Stroes iD, Ulrike Schatz iD, Ursula Kassner iD, Zalmai Hakimi iD, Aletta Falk und 1 weitere

Journal of Comparative Effectiveness Research · 2026-07 · 15 (7)

DOI: 10.57264/cer-2026-0069 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Journal of Comparative Effectiveness Research, 2026-07. Verfasst von Handrean Soran und 12 weiteren Autor:innen. Beteiligte Einrichtung: NIHR/Welcome Trust Clinical Research Facility & Manchester University Hospital NHS Foundation Trust, Manchester, UK. Hauptthemen laut MEDLINE: Hyperlipoproteinemia Type I, Oligonucleotides, Hyperlipoproteinemia Type II. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Familial chylomicronemia syndrome (FCS) is a rare genetic disorder characterized by severe hypertriglyceridemia causing recurrent acute pancreatitis (AP). Since FCS is a genetic deficiency in functional lipoprotein lipase, conventional triglyceride-lowering therapies are ineffective in this metabolic disorder. Apolipoprotein C-III (apoC-III) inhibitors, including volanesorsen and olezarsen, have emerged as targeted treatments for FCS.

Aim

To compare the efficacy and safety of olezarsen 80 mg every four weeks (Q4W) versus volanesorsen 300 mg weekly (QW) in patients with FCS using an anchored matching-adjusted indirect comparison. Materials & methods: Individual patient data from the Balance trial of olezarsen (n = 45) were weighted to match baseline characteristics reported in the APPROACH trial of volanesorsen (n = 66). Outcomes included percent change in fasting triglycerides (TG) and apoC-III at 26 and 52 weeks, and risks of AP events and adverse events at 52 weeks.

Results

At 52 weeks, mean differences in fasting TG and apoC-III were -27.4% (95% CI: -69.4, 14.5) and -21.3% (95% CI: -61.9, 19.3). Relative risks of AP, treatment-emergent adverse events, and serious adverse events were 0.23 (95% CI: 0.01, 5.02), 0.87 (95% CI: 0.66, 1.13) and 0.50 (95% CI: 0.08, 3.26) at week 52. The rate ratio for AP events per patient-year was 0.06 (95% CI: 0.003, 1.41). No comparisons were statistically significant.

Conclusion

In this matching-adjusted indirect comparison, no statistically significant differences in outcomes were observed between olezarsen and volanesorsen in patients with FCS. These findings provide important comparative context in a setting where head-to-head evidence is unavailable.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hyperlipoproteinemia Type IOligonucleotidesHyperlipoproteinemia Type IIHumansMaleFemaleTriglyceridesAdultMiddle AgedApolipoprotein C-IIITreatment OutcomePancreatitis

Stichwörter der Autor:innen

familial chylomicronemia syndromehypertriglyceridemiaindirect treatment comparisonolezarsenvolanesorsen

Substanzen

ISIS 304801TriglyceridesOligonucleotidesApolipoprotein C-IIIolezarsen

Autor:innen und Institutionen

  • NIHR/Welcome Trust Clinical Research Facility & Manchester University Hospital NHS Foundation Trust, Manchester, UK.
  • Ionis Pharmaceuticals Inc., Carlsbad, CA, USA.
  • Evidinno Outcomes Research Inc., Vancouver, BC, Canada.
  • Department of Endocrinology, ULS Sao Joao, Faculty of Medicine, University of Porto (FMUP), Porto, Portugal.
  • Department of Vascular Medicine, Amsterdam University Medical Center, Amsterdam, The Netherlands.
  • Department of Internal Medicine III of the University Hospital Dresden, Technical University of Dresden, Germany.

ORCID-Profile: Asia Sikora Kessler, Montserrat Vera-Llonch, Veronica J Alexander, Paul Serafini, Divya Pushkarna, Erik Stroes, Ulrike Schatz, Ursula Kassner, Zalmai Hakimi, Koo Wilson

Zitieren

APA

Soran, H., Kessler, A. S., Vera-Llonch, M., Alexander, V. J., Serafini, P., Pushkarna, D., Rodrigues, E., Stroes, E., Schatz, U., Kassner, U., Hakimi, Z., Falk, A., & Wilson, K. (2026). Comparative efficacy and safety of olezarsen versus volanesorsen for familial chylomicronemia syndrome: a matching-adjusted indirect comparison. Journal of Comparative Effectiveness Research, 15(7). https://doi.org/10.57264/cer-2026-0069

Vancouver

Soran H, Kessler AS, Vera-Llonch M, Alexander VJ, Serafini P, Pushkarna D, et al. Comparative efficacy and safety of olezarsen versus volanesorsen for familial chylomicronemia syndrome: a matching-adjusted indirect comparison. Journal of Comparative Effectiveness Research. 2026;15(7). doi:10.57264/cer-2026-0069

BibTeX
@article{Soran2026,
  author = {Soran, Handrean and Kessler, Asia Sikora and Vera-Llonch, Montserrat and Alexander, Veronica J and Serafini, Paul and Pushkarna, Divya and Rodrigues, Elisabete and Stroes, Erik and Schatz, Ulrike and Kassner, Ursula and Hakimi, Zalmai and Falk, Aletta and Wilson, Koo},
  title = {Comparative efficacy and safety of olezarsen versus volanesorsen for familial chylomicronemia syndrome: a matching-adjusted indirect comparison},
  journal = {Journal of Comparative Effectiveness Research},
  year = {2026},
  volume = {15},
  number = {7},
  doi = {10.57264/cer-2026-0069}
}
Kostenlos starten →